Search - tctmd.com

Displaying 1 - 20 of 234

Sort: Relevancy | Date

News Opinion CV Team Dispatch

March 2026 Dispatch for the CV Team

L.A. McKeown

March 26, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Daily News

Positive Top-line Results for Retatrutide in Diabetes: TRANSCEND-T2D-1

Caitlin E. Cox

March 19, 2026

News Conference News CRT 2026

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

L.A. McKeown

March 19, 2026

News Conference News CRT 2026

CRT 2026: What to Expect in Washington, DC

L.A. McKeown

March 04, 2026

News Daily News

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Michael O'Riordan

March 03, 2026

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

L.A. McKeown

February 06, 2026

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2026

Caitlin E. Cox

February 02, 2026

News Daily News

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Yael L. Maxwell

January 21, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

WHO Endorses Treating Obesity in Adults With GLP-1s

Todd Neale

December 01, 2025

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

L.A. McKeown

October 25, 2025

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

Advertisement

March 2026 Dispatch for the CV Team

What’s Going to Be Hot at ACC 2026

Positive Top-line Results for Retatrutide in Diabetes: TRANSCEND-T2D-1

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

CRT 2026: What to Expect in Washington, DC

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

TCTMD’s Top 10 Most Popular Stories for January 2026

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

January 2026 Dispatch for the CV Team

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Year in Review: Top Prevention Stories of 2025

December 2025 Dispatch for the CV Team

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

WHO Endorses Treating Obesity in Adults With GLP-1s

October 2025 Dispatch for the CV Team

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content